Clinical Trial

Lactic Acidosis and Prior Metformin Treatment

Study acronym: MALA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial. The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice. This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.
Trial Details
NCT Number NCT07300293
Lead Sponsor University Hospital, Strasbourg, France
Conditions Type 2 Diabetes
Enrollment 100 participants
Start Date 2024-11-06
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-23